Osteoprotegerin ELISA Kit

Produktnummer ABIN411341

Produktdetails Osteoprotegerin ELISA Kit

Target: Osteoprotegerin (TNFRSF11B) (Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B))

Bindungsspezifität: AA 22-401

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Detektionsbereich: 93.7-6000 pg/mL

Untere Nachweisgrenze: 93.7 pg/mL

Applikation: ELISA

Verwendungszweck: Sandwich High Sensitivity ELISA kit for Quantitative Detection of Human OPG

Marke: PicoKine™

Proben: Cell Culture Supernatant, Serum, Plasma (heparin), Plasma (EDTA), Saliva, Urine

Analytische Methode: Quantitative

Spezifität: Expression system for standard: NSO
Immunogen sequence: E22-L401

Kreuzreaktivität (Details): There is no detectable cross-reactivity with other relevant proteins.

Sensitivität: <5pg/mL

Benötigtes Material: Microplate reader in standard size. Automated plate washer. Adjustable pipettes and pipette tips. Multichannel pipettes are recommended in the condition of large amount of samples in the detection. Clean tubes and Eppendorf tubes. Washing buffer (neutral PBS or TBS). Preparation of 0.01M TBS: Add 1.2g Tris, 8.5g Nacl

Immunogen: Expression system for standard: NSO
Immunogen sequence: E22-L401

Anwendungsinformationen

Applikationshinweise: Before using Kit, spin tubes and bring down all components to bottom of tube. Duplicate well assay was recommended for both standard and sample testing.

Kommentare:

Sequence similarities: Contains 2 death domains.

Tissue Specificity: Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.

Plattentyp: Pre-coated

Protokoll: human OPG ELISA Kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. A monoclonal antibody from mouse specific for OPG has been precoated onto 96-well plates. Standards(NSO, E22-L401) and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for OPG is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the human OPG amount of sample captured in plate.

Testdurchführung:

Aliquot 0.1 mL per well of the 6000pg/mL, 3000pg/mL, 1500pg/mL, 750pg/mL, 375pg/mL, 187.5pg/mL, 93.7pg/m human OPG standard solutions into the precoated 96-well plate. Add 0.1 mL of the sample diluent buffer into the control well (Zero well). Add 0.1 mL of each properly diluted sample of human cell culture supernates, serum, plasma(heparin, EDTA), saliva or urine to each empty well. See "Sample Dilution Guideline" above for details. It is recommended that each human OPG standard solution and each sample be measured in duplicate.

Testpräzision:

• Sample 1: n=16, Mean(pg/ml): 843, Standard deviation: 40.5, CV(%): 4.8
• Sample 2: n=16, Mean(pg/ml): 2186, Standard deviation: 111.5, CV(%): 5.1
• Sample 3: n=16, Mean(pg/ml): 3627, Standard deviation: 214, CV(%): 5.9,
• Sample 1: n=24, Mean(pg/ml): 924, Standard deviation: 60.06, CV(%): 6.5
• Sample 2: n=24, Mean(pg/ml): 2570, Standard deviation: 179.9, CV(%): 7
• Sample 3: n=24, Mean(pg/ml): 4085, Standard deviation: 310.46, CV(%): 7.6

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Handhabung: Avoid multiple freeze-thaw cycles.

Lagerung: -20 °C,4 °C

Informationen zur Lagerung: Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles

Haltbarkeit: 12 months

Referenzen für Osteoprotegerin ELISA Kit (ABIN411341)

Häussling, Aspera-Werz, Rinderknecht, Springer, Arnscheidt, Menger, Histing, Nussler, Ehnert: "3D Environment Is Required In Vitro to Demonstrate Altered Bone Metabolism Characteristic for Type 2 Diabetics." in: International journal of molecular sciences, Vol. 22, Issue 6, (2021) (PubMed).

Park, Kim, Kim, Lee, Kim, Park, Chung: "Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma." in: Oncotarget, Vol. 8, Issue 6, pp. 9079-9092, (2018) (PubMed).

Sherief, Dawood, Ali, Sherbiny, Kamal, Elshanshory, Alazez, Alhady, Nour, Mokhtar: "Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker." in: BMC pediatrics, Vol. 17, Issue 1, pp. 69, (2018) (PubMed).

Mamolini, Cervellati, Greco, Carrieri, Massari, Crivellari, Scapoli, Bonaccorsi: "VDR, RANKL and OPG polymorphisms as possible predisposing cofactors of postmenopausal osteoporosis: explorative study in Italian population." in: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, pp. 1-5, (2017) (PubMed).

Cervellati, Romani, Cremonini, Bergamini, Fila, Squerzanti, Greco, Massari, Bonaccorsi: "Higher Urinary Levels of 8-Hydroxy-2'-deoxyguanosine Are Associated with a Worse RANKL/OPG Ratio in Postmenopausal Women with Osteopenia." in: Oxidative medicine and cellular longevity, Vol. 2016, pp. 6038798, (2015) (PubMed).

Chen, Li, Liu, Wang, Xie, Liu, Hou, Chang, Du: "Canonical Wnt signaling is required for Panax notoginseng saponin-mediated attenuation of the RANKL/OPG ratio in bone marrow stromal cells during osteogenic differentiation." in: Phytomedicine : international journal of phytotherapy and phytopharmacology, Vol. 19, Issue 11, pp. 1029-34, (2012) (PubMed).

Taylan, Sari, Akinci, Bilge, Kozaci, Akar, Colak, Yalcin, Gunay, Akkoc: "Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis." in: BMC musculoskeletal disorders, Vol. 13, pp. 191, (2012) (PubMed).

Xu, Wang, Lu, Xu: "Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis." in: Rheumatology international, Vol. 32, Issue 11, pp. 3397-403, (2012) (PubMed).

Details zu Osteoprotegerin

Target: Osteoprotegerin (TNFRSF11B) (Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B))

Andere Bezeichnung: Osteoprotegerin (OPG) (TNFRSF11B Produkte)

Synonyme: CD254 ELISA Kit, ODF ELISA Kit, OPGL ELISA Kit, OPTB2 ELISA Kit, RANKL ELISA Kit, TRANCE ELISA Kit, hRANKL2 ELISA Kit, sOdf ELISA Kit, OCIF ELISA Kit, OPG ELISA Kit, TR1 ELISA Kit, Opg ELISA Kit, ocif ELISA Kit, opg ELISA Kit, tr1 ELISA Kit, TNF superfamily member 11 ELISA Kit, TNF receptor superfamily member 11b ELISA Kit, tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) ELISA Kit, TNF receptor superfamily member 11B ELISA Kit, tumor necrosis factor receptor superfamily member 11b S homeolog ELISA Kit, tumor necrosis factor receptor superfamily, member 11b ELISA Kit, TNFSF11 ELISA Kit, TNFRSF11B ELISA Kit, Tnfrsf11b ELISA Kit, tnfrsf11b.S ELISA Kit

Substanzklasse: Chemical

Hintergrund:

Protein Function: Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. .

Background: Osteoprotegerin(OPG) is identical to osteoclastogenesis inhibitory factor(OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system. The standard product used in this kit is recombinant OPG, a 55KDa glycoprotein.

Synonyms: Tumor necrosis factor receptor superfamily member 11B,Osteoclastogenesis inhibitory factor,Osteoprotegerin,TNFRSF11B,OCIF, OPG,

Full Gene Name: Tumor necrosis factor receptor superfamily member 11B

Cellular Localisation: Secreted.

Gen-ID: 4982

UniProt: O00300